Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1.

Saygin C, Hirsch C, Przychodzen B, Sekeres MA, Hamilton BK, Kalaycio M, Carraway HE, Gerds AT, Mukherjee S, Nazha A, Sobecks R, Goebel C, Abounader D, Maciejewski JP, Advani AS.

Blood Cancer J. 2018 Jan 10;8(1):4. doi: 10.1038/s41408-017-0040-9.

2.

Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.

Ohgami RS, Ma L, Merker JD, Gotlib JR, Schrijver I, Zehnder JL, Arber DA.

Mod Pathol. 2015 May;28(5):706-14. doi: 10.1038/modpathol.2014.160. Epub 2014 Nov 21.

3.

Persistent DNMT3A mutation burden in DNMT3A mutated adult cytogenetically normal acute myeloid leukemia patients in long-term remission.

Sun Y, Shen H, Xu T, Yang Z, Qiu H, Sun A, Chen S, Wu D, Xu Y.

Leuk Res. 2016 Oct;49:102-7. doi: 10.1016/j.leukres.2016.09.001. Epub 2016 Sep 3.

PMID:
27626217
4.

Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia.

Bhatnagar B, Eisfeld AK, Nicolet D, Mrózek K, Blachly JS, Orwick S, Lucas DM, Kohlschmidt J, Blum W, Kolitz JE, Stone RM, Bloomfield CD, Byrd JC.

Br J Haematol. 2016 Oct;175(2):226-236. doi: 10.1111/bjh.14254. Epub 2016 Aug 1.

5.

Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia.

Hou HA, Liu CY, Kuo YY, Chou WC, Tsai CH, Lin CC, Lin LI, Tseng MH, Chiang YC, Liu MC, Liu CW, Tang JL, Yao M, Li CC, Huang SY, Ko BS, Hsu SC, Chen CY, Lin CT, Wu SJ, Tsay W, Tien HF.

Oncotarget. 2016 Feb 23;7(8):9084-101. doi: 10.18632/oncotarget.7000.

6.

FLT3-ITD with DNMT3A R882 double mutation is a poor prognostic factor in Chinese patients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantation.

Tang S, Shen H, Mao X, Dai H, Zhu X, Xue S, Ding Z, Lu J, Wu D, Tang X.

Int J Hematol. 2017 Oct;106(4):552-561. doi: 10.1007/s12185-017-2256-7. Epub 2017 Jun 14.

PMID:
28616699
7.

Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes.

Wu L, Song L, Xu L, Chang C, Xu F, Wu D, He Q, Su J, Zhou L, Xiao C, Zhang Z, Zhao Y, Chen S, Li X.

Tumour Biol. 2016 Apr;37(4):4633-40. doi: 10.1007/s13277-015-4305-2. Epub 2015 Oct 28.

PMID:
26508027
8.

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.

Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, Pigneux A, Wetzler M, Stuart RK, Erba HP, Damon LE, Powell BL, Lindeman N, Steensma DP, Wadleigh M, DeAngelo DJ, Neuberg D, Stone RM, Ebert BL.

Blood. 2015 Feb 26;125(9):1367-76. doi: 10.1182/blood-2014-11-610543. Epub 2014 Dec 30.

9.

Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis.

Thol F, Klesse S, Köhler L, Gabdoulline R, Kloos A, Liebich A, Wichmann M, Chaturvedi A, Fabisch J, Gaidzik VI, Paschka P, Bullinger L, Bug G, Serve H, Göhring G, Schlegelberger B, Lübbert M, Kirchner H, Wattad M, Kraemer D, Hertenstein B, Heil G, Fiedler W, Krauter J, Schlenk RF, Döhner K, Döhner H, Ganser A, Heuser M.

Leukemia. 2017 Jun;31(6):1286-1295. doi: 10.1038/leu.2016.345. Epub 2016 Nov 24.

PMID:
27881874
10.

Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia.

Marková J, Michková P, Burčková K, Březinová J, Michalová K, Dohnalová A, Maaloufová JS, Soukup P, Vítek A, Cetkovský P, Schwarz J.

Eur J Haematol. 2012 Feb;88(2):128-35. doi: 10.1111/j.1600-0609.2011.01716.x. Epub 2011 Nov 17.

PMID:
21967546
11.

Comparison of autologous hematopoietic cell transplantation and chemotherapy as postremission treatment in non-M3 acute myeloid leukemia in first complete remission.

Usuki K, Kurosawa S, Uchida N, Yakushiji K, Waki F, Matsuishi E, Kagawa K, Furukawa T, Maeda Y, Shimoyama M, Ago H, Yamano Y, Yano S, Fujishima N, Takamatsu Y, Eto T, Hidaka M, Matsuoka H, Fukuda T.

Clin Lymphoma Myeloma Leuk. 2012 Dec;12(6):444-51. doi: 10.1016/j.clml.2012.07.004. Epub 2012 Sep 20.

PMID:
22999942
12.

Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor-risk factor in de novo acute myeloid leukemia patients.

Tien FM, Hou HA, Tsai CH, Tang JL, Chen CY, Kuo YY, Li CC, Lin CT, Yao M, Huang SY, Ko BS, Hsu SC, Wu SJ, Tsay W, Tseng MH, Liu MC, Liu CW, Lin LI, Chou WC, Tien HF.

Eur J Haematol. 2018 Jul;101(1):86-94. doi: 10.1111/ejh.13073. Epub 2018 May 22.

PMID:
29624746
13.

Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.

Xu Y, Sun Y, Shen H, Ding L, Yang Z, Qiu H, Sun A, Chen S, Wu D.

Am J Hematol. 2015 Nov;90(11):992-7. doi: 10.1002/ajh.24135.

14.

Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2.

Eisfeld AK, Kohlschmidt J, Mrózek K, Blachly JS, Nicolet D, Kroll K, Orwick S, Carroll AJ, Stone RM, de la Chapelle A, Byrd JC, Bloomfield CD.

Leukemia. 2016 Nov;30(11):2254-2258. doi: 10.1038/leu.2016.196. Epub 2016 Jul 20. No abstract available.

15.

DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.

Ahn JS, Kim HJ, Kim YK, Lee SS, Jung SH, Yang DH, Lee JJ, Kim NY, Choi SH, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim DD.

Biol Blood Marrow Transplant. 2016 Jan;22(1):61-70. doi: 10.1016/j.bbmt.2015.07.030. Epub 2015 Jul 31.

16.

Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations.

Loghavi S, Zuo Z, Ravandi F, Kantarjian HM, Bueso-Ramos C, Zhang L, Singh RR, Patel KP, Medeiros LJ, Stingo F, Routbort M, Cortes J, Luthra R, Khoury JD.

J Hematol Oncol. 2014 Oct 4;7:74. doi: 10.1186/s13045-014-0074-4.

17.

DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations.

Kumar D, Mehta A, Panigrahi MK, Nath S, Saikia KK.

Hematol Oncol Stem Cell Ther. 2018 Jun;11(2):82-89. doi: 10.1016/j.hemonc.2017.09.004. Epub 2017 Oct 18.

18.

[Outcomes of refractory or relapsed DNMT3A + cytogenetically normal acute myeloid leukemia patients followed the therapy including decitabine combined with CAG or CAG-like regimen].

Sun Y, Xu Y, Wu D, Shen H, Yang Z, Qiu H, Chen S, Sun A.

Zhonghua Xue Ye Xue Za Zhi. 2015 Dec;36(12):1025-30. doi: 10.3760/cma.j.issn.0253-2727.2015.12.010. Chinese.

PMID:
26759106
19.

Prognostic significance of DNMT3A mutations in patients with acute myeloid leukemia.

Ibrahem L, Mahfouz R, Elhelw L, Abdsalam EM, Soliman R.

Blood Cells Mol Dis. 2015 Jan;54(1):84-9. doi: 10.1016/j.bcmd.2014.07.015. Epub 2014 Aug 27.

PMID:
25172541
20.

Inferior outcome after allogeneic transplant in first remission in high-risk AML patients who required more than two cycles of induction therapy.

Lim SJ, Lim MJ, Raptis A, Hou JZ, Farah R, Marks SM, Im A, Dorritie K, Sehgal A, Agha M, Felgar R, Lim SH.

Am J Hematol. 2015 Aug;90(8):715-8. doi: 10.1002/ajh.24062.

Supplemental Content

Support Center